ECCRT and IDDI Partner for Continuous Development

Article

ECCRT and IDDI have established a partnership for the continuous development of IDDI global team members.

The European Centre for Clinical Research Training (ECCRT) and the International Drug Development Institute (IDDI) have established a partnership for the continuous development of IDDI global team members.

Announced in a Sept. 9, 2020 press release, the partnership will see ECCRT providing access to the eLearning ‘Virtual Campus’ platform that will enable IDDI’s members to attend training sessions on the International Council for Harmonization good clinical practice and other related topics.

“Good clinical practice (GCP) guidelines and their role in clinical trials [are] key to IDDI’s business,” said Damien Tremolet, CEO of IDDI, in the press release.“ECCRT training services offering precisely matches our needs: online, short, and focused learning combined with workshop training for our global team. It will allow our staff to develop and improve the GCP skills that are essential to ensure the quality, reliability, and integrity of our sponsor’s clinical data.

Benedikt Van Nieuwenhove, managing director of ECCRT, added, in the press release, “We are very pleased to enable IDDI to have all their staff trained to the latest standards, and to allow IDDI to implement employee learning and development on a strategic level.”

Source: IDDI

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.